Study of PLA2R Autoreactive B-Cells and Immune Monitoring in Adults with Membranous Nephropathy Receiving B-Cell Depleting Therapy

What this Trial Is About

Researchers are investigating membranous nephropathy MN, a common cause of nephrotic syndrome in adults, focusing on the role of autoreactive B cells that produce antibodies against the PLA2R receptor. The study aims to understand why some patients respond to B-cell depleting treatments while others do not, by comparing circulating immune cells in responders, non-responders, and healthy controls. This observational study will help identify differences in immune cell behavior related to treatment outcomes. The study includes patients with biopsy-confirmed idiopathic MN who are either planned to receive or have already received B-cell depleting therapy, as well as healthy volunteers without significant illnesses. Researchers will analyze blood samples using biochemical and flow cytometry assays to measure the frequency and activity of various B-cell subsets and other immune cells over a 24-month period. This includes assessments at baseline and multiple follow-up points at 3, 6, 9, 12, and 24 months. Participants will provide blood specimens that will be tested to evaluate the presence and function of autoreactive B cells and other immune cell types. The study will track changes in these immune cells over time, correlating findings with treatment response. The research involves no interventional treatments but focuses on extensive immune monitoring to better understand MN disease mechanisms and predict outcomes. Participation duration varies, with multiple follow-up visits for sample collection and immune profiling.

Autoreactive B Cells in Membranous Nephropathy